Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-HOMA: Azilsartan vs Telmisartan on Insulin Resistance in Essential Hypertension with Type 2 Diabetes
jRCT1080222411
- Sponsor
- Takeda
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial in essential hypertension, type 2 diabetes mellitus (T2DM) and insulin resistance (IR) comparing Azilva arm with Micardis arm (2 arms). Primary endpoint: Change in HOMA-R.
02
Drugs
azilsartantelmisartan
03
Conditions
essential hypertensiontype 2 diabetes mellitus (T2DM)insulin resistance (IR)
Beyond the preview
Go deeper on jRCT1080222411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080222411.